{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Metzger-Filho O"],"funding":["NCI NIH HHS"],"pagination":["3083-90"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3753700"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(25)"],"pubmed_abstract":["Purpose
To retrospectively evaluate the pattern of recurrence and outcome of node-negative breast cancer (BC) according to major subtypes.Patients and methods
In all, 1,951 patients with node-negative, early-stage BC randomly assigned in International Breast Cancer Study Group Trials VIII and IX with centrally reviewed pathology data were included. BC subtypes were defined as triple negative (TN; n = 310), human epidermal growth factor receptor 2 (HER2) positive (n = 369), and hormone receptor positive with high (luminal B-like [LB-like]; n = 763) or low (luminal A-like [LA-like]; n = 509) proliferative activity by Ki-67 labeling index. BC-free interval (BCFI) events were invasive BC recurrence in local, contralateral breast, nodal, bone, or visceral sites. Time to first si"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX."],"pmcid":["PMC3753700"],"funding_grant_id":["U24 CA075362"],"pubmed_authors":["Viale G","Gelber RD","Goldhirsch A","Snyder RD","Price KN","Cardoso F","Coates AS","Crivellari D","Castiglione-Gertsch M","Sun Z","Metzger-Filho O"],"additional_accession":[]},"is_claimable":false,"name":"Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.","description":"Purpose
To retrospectively evaluate the pattern of recurrence and outcome of node-negative breast cancer (BC) according to major subtypes.Patients and methods
In all, 1,951 patients with node-negative, early-stage BC randomly assigned in International Breast Cancer Study Group Trials VIII and IX with centrally reviewed pathology data were included. BC subtypes were defined as triple negative (TN; n = 310), human epidermal growth factor receptor 2 (HER2) positive (n = 369), and hormone receptor positive with high (luminal B-like [LB-like]; n = 763) or low (luminal A-like [LA-like]; n = 509) proliferative activity by Ki-67 labeling index. BC-free interval (BCFI) events were invasive BC recurrence in local, contralateral breast, nodal, bone, or visceral sites. Time to first si","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Sep","modification":"2025-04-04T22:07:50.405Z","creation":"2019-03-27T01:15:06Z"},"accession":"S-EPMC3753700","cross_references":{"pubmed":["23897954"],"doi":["10.1200/jco.2012.46.1574","10.1200/JCO.2012.46.1574"]}}